Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea
· Delayed Price · Currency is KRW 107,400
+700 (0.66%)
Apr 29, 2026, 3:30 PM KST
Kolon TissueGene Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 67,742 | 802.87 | 27,433 | 41,563 | 38,813 | Upgrade
|
| Short-Term Investments | 14,349 | - | - | 16,700 | 200.03 | Upgrade
|
| Cash & Short-Term Investments | 82,091 | 802.87 | 27,433 | 58,263 | 39,013 | Upgrade
|
| Cash Growth | 10124.67% | -97.07% | -52.92% | 49.34% | -30.74% | Upgrade
|
| Accounts Receivable | 179.59 | 237.73 | 183.58 | 33.64 | 334.24 | Upgrade
|
| Other Receivables | 422.16 | 25.84 | 1,195 | 700.99 | 8.56 | Upgrade
|
| Receivables | 601.75 | 263.58 | 1,378 | 734.62 | 342.8 | Upgrade
|
| Inventory | 60.48 | 93.46 | 64.28 | 16.56 | 170.58 | Upgrade
|
| Prepaid Expenses | 870.34 | 1,435 | 1,283 | 1,252 | 1,536 | Upgrade
|
| Other Current Assets | 2,668 | 4,821 | 1,872 | 2,804 | 2,386 | Upgrade
|
| Total Current Assets | 86,292 | 7,415 | 32,031 | 63,070 | 43,449 | Upgrade
|
| Property, Plant & Equipment | 6,122 | 6,971 | 7,061 | 8,157 | 8,945 | Upgrade
|
| Other Intangible Assets | 176.92 | 182.12 | 126.01 | 234.49 | 202.97 | Upgrade
|
| Long-Term Deferred Charges | 311,779 | 200,081 | 87,539 | 30,990 | 5,790 | Upgrade
|
| Other Long-Term Assets | 19,621 | 7,639 | 8,154 | 7,439 | 3,013 | Upgrade
|
| Total Assets | 423,990 | 222,288 | 134,910 | 109,890 | 61,399 | Upgrade
|
| Accounts Payable | 305.93 | 325.38 | 253.51 | 102.69 | 90.35 | Upgrade
|
| Accrued Expenses | 11,756 | 3,200 | 1,709 | 2,529 | 9,901 | Upgrade
|
| Short-Term Debt | 74,204 | 10,894 | - | - | - | Upgrade
|
| Current Portion of Leases | 1,213 | 1,072 | 907.64 | 800.14 | 654.92 | Upgrade
|
| Current Unearned Revenue | 39.05 | 8.95 | 9 | - | - | Upgrade
|
| Other Current Liabilities | 268,164 | 55,610 | 11,424 | 8,172 | 5,496 | Upgrade
|
| Total Current Liabilities | 355,682 | 71,111 | 14,303 | 11,604 | 16,143 | Upgrade
|
| Long-Term Leases | 4,145 | 5,274 | 5,568 | 6,273 | 6,578 | Upgrade
|
| Pension & Post-Retirement Benefits | 82.78 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | 0 | 75.75 | 524.12 | 31 | Upgrade
|
| Total Liabilities | 359,909 | 76,384 | 19,947 | 18,401 | 22,752 | Upgrade
|
| Common Stock | 2.39 | 2.34 | 1.88 | 1.75 | 1.54 | Upgrade
|
| Additional Paid-In Capital | 689,576 | 586,568 | 470,458 | 424,164 | 339,585 | Upgrade
|
| Retained Earnings | -625,439 | -441,532 | -355,250 | -332,401 | -300,732 | Upgrade
|
| Comprehensive Income & Other | -60.5 | 863.7 | -248.43 | -277.49 | -208.79 | Upgrade
|
| Total Common Equity | 64,079 | 145,902 | 114,962 | 91,487 | 38,646 | Upgrade
|
| Shareholders' Equity | 64,081 | 145,904 | 114,963 | 91,489 | 38,648 | Upgrade
|
| Total Liabilities & Equity | 423,990 | 222,288 | 134,910 | 109,890 | 61,399 | Upgrade
|
| Total Debt | 79,561 | 17,240 | 6,476 | 7,074 | 7,233 | Upgrade
|
| Net Cash (Debt) | 2,530 | -16,437 | 20,957 | 51,189 | 31,781 | Upgrade
|
| Net Cash Growth | - | - | -59.06% | 61.07% | -22.18% | Upgrade
|
| Net Cash Per Share | 30.79 | -213.60 | 292.25 | 772.24 | 519.01 | Upgrade
|
| Filing Date Shares Outstanding | 83.22 | 80.04 | 73.21 | 69.97 | 61.91 | Upgrade
|
| Total Common Shares Outstanding | 83.22 | 80.04 | 73.21 | 69.97 | 61.91 | Upgrade
|
| Working Capital | -269,390 | -63,695 | 17,727 | 51,466 | 27,306 | Upgrade
|
| Book Value Per Share | 769.99 | 1822.92 | 1570.27 | 1307.54 | 624.28 | Upgrade
|
| Tangible Book Value | 63,902 | 145,720 | 114,836 | 91,253 | 38,443 | Upgrade
|
| Tangible Book Value Per Share | 767.86 | 1820.65 | 1568.55 | 1304.18 | 621.00 | Upgrade
|
| Machinery | 1,510 | 1,035 | 910.56 | 965.54 | 276.33 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.